Devyser secures a four-year tender in France for Devyser Compact
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Oncology | September 7, 2022
With cancer identified as the leading cause of death in high-income countries, early identification and treatment of cancer, and potential cancer-causing genetic variants, is essential. As the second most common cancer worldwide, and the most frequently diagnosed cancer among women, breast cancer nonetheless has a high survival rate if diagnosed and treated.
Read more about the simple identification of both BRCA1 and BRCA2 genes in the whitepaper:
Next Generation Sequencing – Full gene sequencing of BRCA1 and BRCA2
Devyser, a leading provider of advanced genetic testing solutions, has been awarded a new tender in...
Read More
Devyser is proud to announce that One Lambda Devyser Chimerism and Advyser Chimerism have been...
Read More
Devyser today announced that the Centers for Medicare & Medicaid Services (CMS) has issued its...
Read More
Devyser today announced the enrollment of the first patient in its Devyser Accept cfDNA clinical...
Read More